DALLAS, June 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC (OTC Bulletin Board: ACCPE - News) today announced new strategic and clinical initiatives in the areas of oncology and oncology supportive care. Having successfully divested non-oncology assets in 2005, the Company is now focused on the development of its core oncology product programs which include ProLindac(TM), an innovative polymer-platinum prodrug entering two Phase II clinical trials, MuGard(TM), a supportive care treatment of mucositis for patients undergoing radiation therapy and chemotherapy for cancer, and other early stage oncology compounds that utilize the Company's unique drug delivery platforms. The Company's restructuring efforts included a previously announced financing and a 1-for-5 reverse stock split.
